MET and breast carcinoma: All things considered, this study identifies compound 11b as a strong dual c-Met/VEGFR-2 inhibitor and a promising chemotherapeutic lead candidate for the treatment of breast cancer, highlighting the need for further research into its in vivo effectiveness, selectivity profile, and potential combination regimens.